Miklos Gulyas
Docent vid Institutionen för immunologi, genetik och patologi; Kliniska verksamheter; Klinisk patologi
- E-post:
- miklos.gulyas@igp.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 20
75185 Uppsala - Postadress:
- Rudbecklaboratoriet
75185 Uppsala
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
Akademiska meriter: MD, PhD, Docent
Publikationer
Senaste publikationer
- Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer (2023)
- High iNOS and IL-1β immunoreactivity are features of colitis-associated colorectal cancer tumors, but fail to predict 5-year survival (2023)
- Difficulties in diagnostics of lung tumours in biopsies (2022)
- Comparison of ROS1-rearrangement detection methods in a cohort of surgically resected non-small cell lung carcinomas. (2022)
- Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer (2021)
Alla publikationer
Artiklar
- Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer (2023)
- High iNOS and IL-1β immunoreactivity are features of colitis-associated colorectal cancer tumors, but fail to predict 5-year survival (2023)
- Difficulties in diagnostics of lung tumours in biopsies (2022)
- Comparison of ROS1-rearrangement detection methods in a cohort of surgically resected non-small cell lung carcinomas. (2022)
- Infiltration of NK and plasma cells is associated with a distinct immune subset in non‐small cell lung cancer (2021)
- Localized IgG4-related disease manifested on the tongue (2021)
- High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice (2021)
- Targeted pancreatic beta cell imaging for early diagnosis (2020)
- PPM1D is a neuroblastoma oncogene and therapeutic target in childhood neural tumors (2020)
- Blood brain barrier (2020)
- Use of cholesterol and soluble tumour markers CEA and syndecan-2 in pleural effusions in cases of inconclusive cytology (2019)
- COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer. (2018)
- PD-L1 immunohistochemistry in clinical diagnostics of lung cancer (2017)
- PD-L1 immunohistochemistry in clinical diagnostics (2017)
- An Overview of Multimodal Neuroimaging Using Nanoprobes (2017)
- COX-2 Expression Does Not Predict Outcome of Celecoxib in Addition to Standard Chemotherapy in Advanced Non-Small Cell Lung Cancer (2015)
- Prognostic impact of COX-2 in non-small cell lung cancer (2015)
- Early Events in Xenograft Development from the Human Embryonic Stem Cell Line HS181-Resemblance with an Initial Multiple Epiblast Formation (2011)
- Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer.
- COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
